Ozempic vs Wegovy vs Mounjaro: Side Effects

Written by the GLP-1 Coach editorial team. Last updated August 7, 2026.

Ozempic, Wegovy, Mounjaro, and Zepbound are often discussed as interchangeable, but they're not identical — and the side effect profile differs enough between them that it's worth understanding before comparing notes with someone on a different medication (or wondering why your experience doesn't match what you've read).

What's the core difference — GLP-1 alone vs dual-agonist?

Ozempic and Wegovy (both semaglutide) work as GLP-1 receptor agonists — they act on one hormonal pathway involved in appetite regulation and gastric emptying.

Mounjaro and Zepbound (both tirzepatide) are dual GIP/GLP-1 receptor agonists — they act on two pathways instead of one. This is part of why tirzepatide-based medications tend to show somewhat greater average weight loss in clinical trials, but it also means the side effect experience isn't always a direct match to semaglutide.

Ozempic and Wegovy are the same active compound at different dose ranges (Ozempic is approved for diabetes, Wegovy for weight management, with different titration schedules) — so side effect patterns between them are usually more similar to each other than either is to Mounjaro or Zepbound.

	Ozempic	Wegovy	Mounjaro	Zepbound
Active compound	Semaglutide	Semaglutide	Tirzepatide	Tirzepatide
Mechanism	GLP-1	GLP-1	GIP/GLP-1 dual	GIP/GLP-1 dual
FDA indication	Type 2 diabetes	Weight management	Type 2 diabetes	Weight management
Max dose	2 mg weekly	2.4 mg weekly	15 mg weekly	15 mg weekly

How do nausea and GI side effects compare?

Both drug classes cause nausea, primarily through slowed gastric emptying. In practice, many people report the nausea pattern feels broadly similar between semaglutide and tirzepatide, though individual tolerance varies widely — some people find one medication noticeably more tolerable than the other, without a consistent pattern across the population.

Constipation tends to be a common thread across both drug classes, often more persistent than nausea and sometimes underreported because it doesn't resolve as cleanly over the first few weeks the way nausea often does.

Is appetite suppression stronger on Mounjaro?

Because tirzepatide acts on two receptor pathways, some people report a more pronounced appetite suppression on Mounjaro or Zepbound compared to semaglutide at equivalent points in titration. This isn't universal, but it's a commonly reported difference — and it means protein and hydration targets may need even more deliberate attention on a dual-agonist medication, since appetite suppression working "too well" can make it harder to eat enough of anything.

Do energy levels differ between medications?

Early-phase fatigue is commonly reported across all four medications, generally attributed to reduced calorie intake combined with the body adjusting to the new hormonal signaling. This tends to improve over the first several weeks as eating patterns stabilize, regardless of which specific medication is being used.

Why do titration schedules matter so much?

Wegovy and Zepbound (the weight-management-labeled versions) follow more gradual, structured dose-escalation schedules than the diabetes-labeled Ozempic and Mounjaro, which can sometimes be titrated faster depending on the prescriber's approach. This matters because a faster titration schedule often means a more compressed, more intense side-effect window — so two people on "the same" medication class can have meaningfully different experiences based on how quickly their dose increased. For the full picture of what changes at each dose step, including how the protein problem worsens at higher doses, see the Ozempic dose and titration schedule explained.

What does this mean practically?

If you're comparing notes with someone on a different GLP-1 medication and your experiences don't match, that's expected — different receptor targets, different titration speeds, and individual variation all play a role. The more useful comparison isn't "how does my experience compare to someone else's," but "how does my week 6 compare to my own week 2" — which is where tracking your own pattern over time tends to be more informative than comparing across medications or people.

The bottom line

Bottom line: Ozempic and Wegovy are the same molecule at different target doses. Mounjaro and Zepbound are a different drug class (dual GIP/GLP-1) that tends to produce more weight loss and often stronger appetite suppression. Side-effect patterns overlap heavily across all four — the more useful comparison is your own week-over-week trajectory, not someone else's medication.

Final Thoughts

Which medication is "best" depends less on the molecule than on which one you tolerate and stay on consistently. If you're on tirzepatide (Mounjaro or Zepbound) and the appetite suppression feels aggressive, protein and hydration targets need even more deliberate attention — the drug is doing more of the work, which paradoxically raises the stakes on what you eat. If a weight-loss plateau emerges while you're on any of these medications, it's worth checking whether low protein is disguising itself as a plateau before attributing it to the medication. If you're on semaglutide (Ozempic or Wegovy) and results feel slower, that doesn't necessarily mean switching is the answer; consistency and titration timing usually matter more than the choice of molecule.

The site's role isn't to tell you which medication to be on — that's your prescriber's call, based on your history, insurance coverage, and clinical goals. What we can do is help you see your own week-by-week pattern clearly, so the comparisons that matter (your week 6 vs your week 2) are actually visible instead of guessed at.

---

Related:

• Ozempic Dose Explained: The Titration Schedule and What Changes at Each Step
• Is Your Weight-Loss Plateau Actually Muscle Loss in Disguise?
• Muscle Loss After Stopping GLP-1s: Why You Likely Regain Fat, Not Muscle

---

This article is educational and not a substitute for medical advice. Medication choice and dosing should always be determined with your prescriber based on your individual health profile.